Detalles de la búsqueda
1.
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
N Engl J Med
; 388(21): 1966-1980, 2023 May 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37224198
2.
Washout Periods in Inflammatory Bowel Disease Trials: A Systematic Literature Review and Proposed Solutions.
Clin Gastroenterol Hepatol
; 22(4): 896-898.e13, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37743039
3.
Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease Progression.
Clin Gastroenterol Hepatol
; 2024 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38428709
4.
Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials.
Clin Gastroenterol Hepatol
; 22(4): 810-820.e7, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37806372
5.
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease.
Am J Gastroenterol
; 2024 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38235763
6.
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
BMC Gastroenterol
; 24(1): 121, 2024 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38539103
7.
Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
Gut
; 72(4): 644-653, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36343979
8.
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Lancet
; 399(10341): 2113-2128, 2022 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35644166
9.
Induction Efficacy of Upadacitinib in Therapy-Refractory Crohn's Disease: A Retrospective Case Series.
Clin Gastroenterol Hepatol
; 21(2): 532-534.e3, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35033640
10.
Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 21(4): 1050-1060.e9, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36029969
11.
Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.
Clin Gastroenterol Hepatol
; 21(13): 3387-3396.e1, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37391059
12.
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial.
Clin Gastroenterol Hepatol
; 2023 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37993033
13.
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Gastroenterology
; 162(6): 1650-1664.e8, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35134323
14.
Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDS With Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology (PURE) Study.
Clin Gastroenterol Hepatol
; 21(10): 2649-2659.e16, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36528284
15.
Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study.
Am J Gastroenterol
; 118(1): 121-128, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36066459
16.
Evaluation of Intestinal Fibrosis with 68Ga-FAPI PET/MR Enterography in Crohn Disease.
Radiology
; 307(3): e222389, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36853176
17.
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.
Ann Rheum Dis
; 82(8): 1049-1058, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37137672
18.
Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn's Disease.
J Clin Gastroenterol
; 57(9): 913-919, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36227009
19.
End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis.
Scand J Gastroenterol
; 58(1): 7-14, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35909369
20.
Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission.
Dig Dis Sci
; 68(6): 2658-2666, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36645636